Personalis (PSNL) reported Q4 FY2025 revenue of USD 17.3 million, with a net loss of USD 23.8 million (loss per share USD 0.26). For FY2025, revenue was USD 69.6 million and net loss was USD 81.3 million (loss per share USD 0.91). FY2025 clinical test revenue was USD 2.0 million (more than double), and clinical test volume reached 16,233 tests (nearly 400% increase); in Q4, clinical test revenue was USD 0.9 million and clinical test volume was 6,183 tests (41% sequential increase). Personalis ended FY2025 with about USD 240.0 million in cash, cash equivalents and short-term investments, including about USD 109.0 million in net proceeds from its ATM program at a weighted-average price of USD 8.43 per share. Business updates included Medicare coverage approval in Q4 for surveillance of cancer recurrence in breast cancer patients and Medicare coverage for Stage I–III non-small cell lung cancer in Q1 FY2026. The company also highlighted TRACERx data published in Cell supporting its ultrasensitive MRD approach and VHIO data published in Clinical Cancer Research on ctDNA dynamics across solid tumors treated with immunotherapy. For FY2026, Personalis guided for total revenue of USD 78.0 million to USD 80.0 million, clinical revenue of USD 10.0 million to USD 11.0 million with clinical volume of 43,000 to 45,000 tests, gross margin of 15% to 20%, net loss of about USD 105.0 million, and cash usage of about USD 100.0 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260226102081) on February 26, 2026, and is solely responsible for the information contained therein.
Comments